Bone marrow niche regulation of disseminated tumor cell dormancy, reactivation, and metastasis.
播散性肿瘤细胞休眠、重新激活和转移的骨髓生态位调节。
基本信息
- 批准号:10358068
- 负责人:
- 金额:$ 11.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-10 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibodiesAwardBiocompatible MaterialsBioinformaticsBiological AssayBiopsyBiopsy SpecimenBone MarrowBone Marrow CellsBone Marrow Stem CellBone marrow biopsyBreast Cancer CellBreast Cancer ModelBreast Cancer PatientCancer BiologyCause of DeathCell CommunicationCell LineCellsCharacteristicsClinicalClinical OncologyCoculture TechniquesConsultCuesCytometryDataDevelopmentDiagnosisElementsEstrogen receptor positiveEvaluationExhibitsGelHematopoieticHormone ResponsiveHormonesHydrogelsImageImmuneImmunocompetentIn VitroInflammationLeadLearningLifeMaintenanceMechanicsMentorsMicroscopyModelingMolecular BiologyMusNatureNeoplasm MetastasisNormal tissue morphologyOpticsParacrine CommunicationPathologyPatientsPhasePhenotypePlayPopulationPreventionPrognostic FactorRecurrenceRecurrent diseaseRegulationRegulatory PathwayRelapseResearchRiskRoleSamplingSeriesSourceStressful EventSumTestingThree-Dimensional ImagingTissuesTrainingWorkbasebonecancer cellcancer stem cellcue reactivityexperiencehigh dimensionalityhigh riskhuman diseasein vivomalignant breast neoplasmmechanotransductionmouse modelneoplastic cellnovelpredictive modelingpreventprogramsprotein biomarkersrecruitsingle-cell RNA sequencingstemstem cell nichetherapeutic developmenttherapeutic targettherapy developmenttissue stem cellstumor
项目摘要
PROJECT SUMMARY / ABSTRACT
Metastatic relapse may occur in patients with ER+ breast cancer decades after original diagnosis. Most breast
cancer related deaths are caused by metastasis and thus identifying at-risk patients and developing therapies to
prevent reactivation are a crucial challenge. These efforts have been impeded by a lack of understanding of
cancer cell dormancy in the bone marrow, believed to be the cellular source of metastatic relapse. It is not well
understood how tumor cells interact with the bone marrow microenvironment and how these interactions regulate
tumor cell dormancy and escape. My proposed research seeks to develop a mouse model of dormancy and
investigate the spatial organization of the bone marrow niche in patient samples in the mentored K99 phase and
develop a biomaterial model of dormancy in the independent R00 phase. I hypothesize (i) cancer stem cells are
a subset of disseminated tumor cells responsible for metastatic relapse and (ii) the bone marrow niche, including
the healthy stem cell niche, facilitates dormancy and reactivation of these cells. In Aim 1, I will develop a novel
mouse model of hormone responsive breast cancer dormancy in bone marrow and evaluate the presence,
phenotype, and microenvironmental regulation of disseminated tumor cells using optical tissue clearing/3D
imaging of whole bone. In Aim 2, I will investigate the hypothesis that tumor cell interactions with the bone marrow
niche control tumor cell phenotype via high dimensional spatial analysis of bone marrow biopsies from patients
with breast cancer including imaging mass cytometry (IMC) and spatial single cell RNA sequencing (scRNAseq).
In Aim 3, I will develop a biomaterial model of the dormant bone marrow niche via creating mechanical mimics
of the three distinct compartments of bone marrow and evaluate the role of mechanosensing in induction and
maintenance of dormancy. In the K99 phase of the award, Prof Max Wicha will serve as my main mentor. Dr.
Wicha is a pioneer in the cancer stem cell field and is an expert in breast cancer biology and metastasis. I will
work with and consult my collaborators and mentoring team, including Prof Fei Wen (imaging mass cytometry),
Evan Keller (single cell spatial analysis program), Dr. Dafydd Thomas (pathology core), Prof Gary Luker
(microscopy), Prof Monika Burness (breast cancer clinical oncology) and Prof Sofia Merjaver (breast cancer
molecular biology). My K99 training will consist of developing a novel mouse model of bone marrow dormancy
and learning bioinformatics approaches to analyze spatial contributions to cellular phenotype in IMC and
scRNAseq data to propel me toward developing a synthetic dormant bone marrow niche mimic using
biomaterials during the independent R00 phase. In sum, the proposed research will address an urgent, unmet
need to identify the role of the bone marrow niche in breast cancer dormancy and reactivation, which may provide
a path forward for identifying patients at higher risk of metastasis and developing therapies against reactivation.
项目摘要/摘要
ER阳性乳腺癌患者在最初诊断数十年后可能会发生转移复发。最丰胸
癌症相关死亡是由转移引起的,从而识别高危患者并开发治疗方法
防止重新激活是一项至关重要的挑战。这些努力因缺乏对
癌细胞在骨髓中处于休眠状态,被认为是转移复发的细胞来源。情况不太好
了解肿瘤细胞如何与骨髓微环境相互作用,以及这些相互作用如何调节
肿瘤细胞休眠和逃逸。我提出的研究旨在开发一种小鼠休眠和
在指导的K99期和K99期的患者样本中研究骨髓生态位的空间组织
建立独立R00阶段休眠的生物材料模型。我假设(I)癌症干细胞是
导致转移性复发的一组播散性肿瘤细胞和(Ii)骨髓壁龛,包括
健康的干细胞利基有助于这些细胞的休眠和重新激活。在目标1中,我将开发一部小说
荷尔蒙反应性乳腺癌小鼠模型的建立及对其存在的评价
应用光学组织清除/3D技术研究播散性肿瘤细胞的表型和微环境调控
整个骨骼的成像。在目标2中,我将研究肿瘤细胞与骨髓相互作用的假设
通过对患者骨髓活检组织的高维空间分析控制肿瘤细胞表型
对于乳腺癌,包括成像质量细胞术(IMC)和空间单细胞RNA测序(ScRNAseq)。
在目标3中,我将通过创建机械模拟来开发休眠的骨髓壁龛的生物材料模型
三个不同的骨髓隔室,并评估机械感觉在诱导和
保持休眠状态。在K99奖项阶段,Max Wicha教授将担任我的主要导师。Dr。
Wicha是癌症干细胞领域的先驱,也是乳腺癌生物学和转移方面的专家。这就做
与我的合作者和指导团队合作并咨询,包括费文教授(成像质量细胞术),
Evan Keller(单细胞空间分析程序)、Dafydd Thomas博士(病理学核心)、Gary Luker教授
(显微镜),Monika Burness教授(乳腺癌临床肿瘤学)和Sofia Merjaver教授(乳腺癌
分子生物学)。我的K99训练将包括开发一种新的骨髓休眠小鼠模型
学习生物信息学方法分析IMC和IMC细胞表型的空间贡献
ScRNAseq数据,以推动我开发一种使用
独立R00阶段的生物材料。总而言之,拟议的研究将解决一个紧急的、未得到满足的
需要确定骨髓生态位在乳腺癌休眠和再激活中的作用,这可能会提供
为识别转移风险较高的患者和开发防止复发的治疗方法提供了一条前进的道路。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Grace Gilmore Bushnell其他文献
Grace Gilmore Bushnell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Grace Gilmore Bushnell', 18)}}的其他基金
Bone marrow niche regulation of disseminated tumor cell dormancy, reactivation, and metastasis.
播散性肿瘤细胞休眠、重新激活和转移的骨髓生态位调节。
- 批准号:
10569646 - 财政年份:2022
- 资助金额:
$ 11.17万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 11.17万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 11.17万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 11.17万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 11.17万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 11.17万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 11.17万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 11.17万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 11.17万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 11.17万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 11.17万 - 项目类别:














{{item.name}}会员




